AI Brain Imaging Eases Alzheimer's Treatment Monitoring
Clinicians prescribing anti-amyloid therapies may gain AI-assisted MRI tools to track brain changes during treatment.
Updated on Nov. 2, 2026 in Alzheimer’s
Live Poll
Would you trust a doctor who used AI to read your brain scan?
Seoul-based Neurophet has partnered with RapidAI to integrate its AI brain imaging tools into RapidAI's Rapid Enterprise Platform, accelerating commercial access in the U.S. The partnership centers on Neurophet AQUA AD Plus, a tool designed to support clinicians prescribing Alzheimer's treatments.
Why it matters
Anti-amyloid therapies for Alzheimer's can carry treatment-related side effects that are visible on brain imaging, so better tools for reading those scans affect how safely these drugs can be monitored. The companies say the integration places this imaging into workflows radiologists and care teams already use, which may make monitoring more routine.
This is a commercial partnership announcement, and the source reports no study design, sample size, or measured performance for the imaging tools. The supporting figures describe RapidAI's overall platform reach rather than validation of Neurophet's technology specifically.
The players
Neurophet
A Seoul-based artificial intelligence company developing brain-imaging tools for diagnosing and treating brain disorders, including Alzheimer's disease.
RapidAI
A global enterprise clinical AI company whose imaging solutions are used by more than 2,500 hospitals across 100 countries.
The details
Neurophet AQUA AD Plus uses AI-powered analysis of brain MRI scans to identify and quantify hypointense and hyperintense lesions, the spots that appear on imaging and can signal changes in the brain. The tool is designed to support prescribing decisions for Alzheimer's treatments and to help track imaging findings relevant to anti-amyloid therapy side effects. Radiologists will see AI-generated insights through Rapid Navigator Pro, while clinicians will access results through the Rapid Mobile App.
Timeline
Neurophet was founded in 2016.
The partnership with RapidAI was announced on November 2, 2026.
Neurophet plans to begin full-scale distribution of Neurophet AQUA AD Plus to U.S. memory disorders centers.
Health Landscape
Anti-amyloid treatments have added a new monitoring burden, since clinicians must watch brain scans for side effects over the course of therapy. Tools like Neurophet AQUA AD Plus aim to make that monitoring more consistent as these treatments become more widely prescribed.
If you or a family member is considering or receiving an anti-amyloid Alzheimer's treatment, the imaging monitoring your care team uses may become more standardized as these tools spread. It is worth asking your neurologist or memory clinic how brain imaging will be used to track your safety during treatment.
The takeaway
Brain imaging is becoming a central part of safely managing Alzheimer's treatments, and AI tools are being built to fit into existing radiology workflows. If you are on or considering these therapies, ask your physician what imaging is planned and why.
What happens next
Neurophet plans to begin full-scale distribution of Neurophet AQUA AD Plus to U.S. memory disorders centers, though the source does not give a specific date for that rollout.
Further reading
For more on the condition behind this imaging work, explore our coverage of Alzheimer's.
Live Poll
Would you trust a doctor who used AI to read your brain scan?
